Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452121 | 0.80 | SLC6A4 (0.38) | CCR2CYP2C19ESR1ESR2 | |
| SCHEMBL4438908 | 0.77 | CCR2 (0.43) | CCR2CYP2C19ALDH1A1TP53HPGD | |
| SCHEMBL4442488 | 0.77 | CCR2 (0.43) | CCR2CYP2C19OPRM1OPRK1ALDH1A1 | |
| SCHEMBL4450078 | 0.70 | CCR2 (0.47) | CCR2CYP2C19ALDH1A1TP53HPGD | |
| SCHEMBL15011538 | 0.69 | OPRM1 (0.43) | CCR2CYP2C19OPRM1OPRK1 | |
| SCHEMBL21023363 | 0.68 | SLC6A3 (0.43) | CYP2C19 | |
| SCHEMBL4450387 | 0.67 | CCR2 (0.40) | CCR2CYP2C19LMNAESR1ESR2 | |
| SCHEMBL15010304 | 0.66 | CCR2 (0.37) | CCR2CYP2C19OPRM1OPRK1 | |
| SCHEMBL14248553 | 0.65 | CCR2 (0.37) | CCR2CYP2C19ALDH1A1LMNAESR1 | |
| SCHEMBL14248637 | 0.64 | CCR2 (0.36) | CCR2CYP2C19ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299111-A1 | (ALKYLPHENYL) ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL) ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-1908743-A1 | (ALKYLPHENYL)ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL)ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299111-A1 | (ALKYLPHENYL) ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL) ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | CCNA2, ACACB, PARP8 | CCR2 323/4885CYP2C19 936/4885OPRM1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.